DSIP Dosage: Community Sleep Protocols
Last updated September 26, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← DSIP encyclopedia entry · See also: Epithalon dosage · Regulatory tracker
DSIP is investigational and not FDA approved, and its human evidence is limited and mixed — even the sleep effect that gives it its name is not well established in people. There is no label or validated dose. The figures below reflect community practice, documented for education — not instructions for use.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
The short version
DSIP (delta sleep-inducing peptide) is a naturally occurring nine–amino-acid peptide that got its name from early research linking it to deep, slow-wave (delta) sleep. It is used in community protocols for sleep and stress, but the honest framing is that decades after its discovery the human evidence remains thin and inconsistent — its effects are not as clearly established as the name implies, which is the key context for any dose.
What community protocols report
Community-reported. Amounts users report, recorded for education. Not a recommendation, and not a dose any study has shown to be safe or effective.
| Parameter | Commonly reported |
|---|---|
| Amount | ~100–500 mcg per dose |
| Frequency | Once daily |
| Timing | At bedtime |
| Route | Subcutaneous |
Bedtime dosing follows the obvious logic of a sleep peptide. But the modest microgram amounts and the bedtime timing are conventions inherited from how DSIP is discussed, not a schedule validated by robust human sleep studies — and the underlying effect itself is uncertain.
Where DSIP stands legally
DSIP was on the FDA 503A Category 2 list and, on April 15, 2026, was among the peptides removed from Category 2 (FDA announced the removals that day, effective within seven days; its Category 2 page reflects them as of April 22, 2026) after nominations were withdrawn — which is not approval. On July 24, 2026 the PCAC voted 6–7, with one abstention, against recommending it (as emideltide) for the 503A Bulks List — the only one of the seven peptides reviewed that the committee turned down (the vote and FDA's briefing). It remains outside the approved-medicine framework; see the Regulatory Status Tracker.
Reconstitution basics
DSIP is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before a microgram dose can be measured. The Reconstitution Calculator converts vial strength and diluent volume into an exact syringe draw; it cannot verify the contents of an unregulated vial.
Frequently asked questions
Does DSIP reliably improve sleep?
The human evidence is limited and mixed; despite its name, a consistent, well-demonstrated sleep effect in people has not been firmly established.
Is it sedating like a sleep drug?
It is not a sedative-hypnotic and does not work like one; its proposed role relates to sleep-regulating signaling, which is part of why effects are subtle and inconsistent in studies.
Is it approved now that it's off Category 2?
No. Removal from Category 2 is procedural, not approval: at its July 24, 2026 review the PCAC voted 6–7, with one abstention, against recommending it (as emideltide) for the 503A Bulks List. As of September 26, 2026 it remains outside the approved-medicine framework.
Sources
- Schoenenberger GA, Monnier M. Characterization of delta sleep-inducing peptide (DSIP).
- U.S. FDA — 503A bulk drug substances list update and Category 2 removals, April 15, 2026; PCAC meeting notice for July 23–24, 2026 (emideltide).
Medical disclaimer: Education only, not medical advice. DSIP is investigational and not approved for human use. Dosing figures reflect community reports, not a recommendation. Do not self-administer; consult a licensed clinician.